The supply of

Fusidic Acid 2% Cream

by Community Pharmacists for

Management of Impetigo

On Isle of Wight

This Patient Group Direction (PGD) must only be used by community pharmacists who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Version number: 2.0

Change history

<table>
<thead>
<tr>
<th>Version number</th>
<th>Change details</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Production of PGD from National Health Service England (NHSE) approved PGD</td>
<td>Oct 15</td>
</tr>
<tr>
<td>1.1</td>
<td>Isle of Wight Council suggested changes</td>
<td>Jan 16</td>
</tr>
<tr>
<td>1.2</td>
<td>Amendments to training for pharmacist</td>
<td>Apr 16</td>
</tr>
<tr>
<td>2.0</td>
<td>Review</td>
<td>Feb 18</td>
</tr>
</tbody>
</table>

PGD approval date/ Valid from: 1.3.2018
CCG implementation date: 1.4.2018
Review date: 1.1.2020
Expiry Date: 31.3.2020
### Fusidic Acid PGD Accountability Record

#### PGD Development Group

<table>
<thead>
<tr>
<th>Name</th>
<th>Job title and organisation</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
</table>
| Lead author        | Caroline Allen  
                   Deputy Head of Medicines Management                         |           | 1-3-18|
| Lead pharmacist     | David France  
                   Medicines Management Pharmacist                                |           | 1-3-18|
| Community Pharmacy | Richard Buxton  
                   Professional Services Development Manager Community Pharmacy South Central |           |       |

#### PGD Authorisation

This PGD has been approved and authorised for use by:

Commissioning organisation: NHS IOW CCG Clinical Commissioning Committee Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Authorising Professional</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Oommen John</td>
<td>Clinical Commissioning Group (CCG) Clinical Governance lead</td>
<td></td>
<td>9/3/18</td>
</tr>
<tr>
<td>Melanie Rogers</td>
<td>CCG Director of Nursing and Quality</td>
<td></td>
<td>23/2/18</td>
</tr>
<tr>
<td>Tracy Savage</td>
<td>CCG Assistant Director of Medicines Optimisation / PGD Lead</td>
<td></td>
<td>24/2/18</td>
</tr>
</tbody>
</table>

#### Provider Organisation (adoption needed)

<table>
<thead>
<tr>
<th>Name</th>
<th>Authorising Professional</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>On behalf of Community Pharmacy company</td>
<td>Manager of healthcare professional</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please note:

Individuals signing as the ‘manager of the healthcare professionals using the PGD’ have the responsibility to ensure ALL staff working to the PGD legally recognised to do so. Staff should be trained and competent, and their competency should be regularly updated.
## Requirements of community pharmacists working under the PGD

<table>
<thead>
<tr>
<th>Qualifications and professional registration</th>
<th>Pharmacist currently registered with General Pharmaceutical Council (GPhC)</th>
</tr>
</thead>
</table>
| Initial training                              |  - Completion of education in both the legal and professional aspects of PGD administration and the supply of medicines using:  
  - GPhC codes of Professional Conduct  
  - Legal framework of PGD’s  
  - Medicine, Ethics and Practice: Royal Pharmaceutical Society (RPS)  
  - Successful completion of self-assessment of competency form in the use of this medicine for the indications stated  
  - The Pharmacist must complete electronic declaration (enrolment) via PharmOutcomes, by clicking on Fusidic Acid PGD tab. |
| Competency assessment (CPPE Declaration of Competence) | College of Pharmacy Postgraduate Education (CPPE) distance learning:  
  - CPPE learning pack ‘Responding to Minor Ailments’ and learning assessment [https://www.cppe.ac.uk/programmes/l/respmin-p-02](https://www.cppe.ac.uk/programmes/l/respmin-p-02)  
  - Guidelines for use of this PGD including NICE Clinical Knowledge Summaries [https://cks.nice.org.uk/impetigo](https://cks.nice.org.uk/impetigo)  
  - Optional – CPPE distance learning module Dermatology pocket guide: common skin conditions explained [https://www.cppe.ac.uk/programmes/l/dermatology-p-01/](https://www.cppe.ac.uk/programmes/l/dermatology-p-01/) |
| Ongoing training and competency               |  - The Pharmacist is responsible for keeping him/herself aware of any changes to the recommendations for the medicine listed.  
  - It is the responsibility of the individual to keep up-to-date with continued professional development and to work within the limitations of their own individual scope of practice. |

---

Retain a copy of each version of the Patient Group Direction for ten years. A copy of this PGD should be given to the CCG, the healthcare professional(s) listed above, their manager(s) and the original is to be retained by the Prescribing Advisor/Manager.
The supply of Fusidic Acid 2% Cream by community pharmacists for Impetigo in Isle of Wight NHS minor ailments

<table>
<thead>
<tr>
<th>Clinical condition or situation to which this PGD applies</th>
<th>Treatment of minor staphylococcal skin infections (Impetigo)</th>
</tr>
</thead>
</table>
| Inclusion criteria                                       | • Patient presenting with minor impetigo limited to a few lesions in one area of the body. Rash consists of vesicles that weep and then dry to form yellow-brown crusts  
  • Parental consent must be obtained for treating a child under the age of 16  
  • Patient must be present at consultation |
| Exclusion criteria                                        | • Multiple site skin infections  
  • Previous impetigo infection in last 3 months  
  • Allergy to any component of the cream  
  • Pregnancy and/or breastfeeding  
  • Patient refuses treatment  
  • Patient presents with any other skin condition on the same area of the body as the impetigo  
  • Concerns regarding patient compliance with topical medication. |
| Cautions (including any relevant action to be taken)       | • Cellulitis can be mistaken for impetigo. If any doubt over diagnosis refer to GP for advice and treatment  
  • Infections around eyes and mucous membranes may require systemic antibiotics as fusidic acid cream should not be used in these areas. If in doubt refer to GP for suitable treatment. |
| Arrangements for referral for medical advice               | • Contact details of services available to be provided to patient, with hours of opening.  
  • Pharmacist to provide written summary of assessment for patient to via Pharm Outcomes electronic transfer to GP, including reason for referral |
| Action to be taken if patient excluded                     | • Refer to GP for advice and treatment  
  • Provide with information leaflet giving extra information about condition and management  
  • Advise on support for self-care where appropriate |
### Details of the medicine/ Description of treatment

<table>
<thead>
<tr>
<th>Name, form and strength of medicine</th>
<th>Fusidic Acid 2% cream (15g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BNF Chapter Category</td>
<td>5.2</td>
</tr>
<tr>
<td>Legal category</td>
<td>Prescription Only Medicine (POM)</td>
</tr>
<tr>
<td>Dose and frequency</td>
<td>Apply three times a day for 7 days</td>
</tr>
<tr>
<td>Route/method of administration</td>
<td>Topical</td>
</tr>
<tr>
<td>Total Quantity to be administered and/or supplied</td>
<td>1 x 15g tube</td>
</tr>
<tr>
<td>Maximum or minimum treatment period</td>
<td>7 days</td>
</tr>
<tr>
<td>Adverse effects</td>
<td>For full list of Adverse Drug reactions (ADR’s) see British National Formulary (BNF)/ Summary of Product Characteristics (SmPC)</td>
</tr>
<tr>
<td>Records to be kept</td>
<td>The following will be recorded on PharmOutcomes in the patient records:</td>
</tr>
</tbody>
</table>

- The diagnosis (Impetigo)
- Treatment recommended (Fusidic Acid Cream)
- Quantity supplied (1 x 15g tube)
- Batch number and expiry date
- Name of manufacturer
- Duration of treatment (7 days)
- Date of supply
- Name of the individual assessing the patient and making the supply
Copies of records and oral consent via PharmOutcomes must be kept for 2 years
Information must be sent to the GP for entry into the patient's records

Document any allergies and other adverse drug reactions clearly in the patient records and inform GP and other relevant practitioners/carers for further reporting and action

### Patient information

**Written information to be given to patient or carer**

- Wash hands before and after applying cream
- Where possible remove scabs by bathing in warm water before applying the cream
- Impetigo is a very infectious condition. It is important to prevent infection spreading by using own flannel and towels (Hot wash after use)
- Do not scratch or pick spots
- Suggest applying cream three times a day on school days and four times a day at other times
- Inform school / nursery of condition. Children should stay away from school until lesions are dry and scabbed over, or, if the lesions are still crusted or weeping for 48 hours after antibiotic treatment has started
- Reassure that impetigo usually heals completely without scarring and that serious complications are rare
- Do not share the cream with anyone else
- Advise on potential adverse reactions – if any develop stop treatment and contact GP
- Fusidic acid is for cutaneous use only, therefore advise to avoid contact with eyes and mucous membranes.
- Advise patient to see GP if there is no significant improvement after 7 days.
- Extended and recurrent use may increase the risk of contact sensitisation and the development of antibiotic resistance. Patients should be advised to discard remaining cream after treatment period.
- Patient information leaflet should be provided [http://patient.info/health/impetigo-leaflet](http://patient.info/health/impetigo-leaflet)

**Follow-up advice to be given to patient or carer**

- If no significant improvement after 7 days – seek medical advice from GP
- If symptoms worsen or appear in multiple locations see GP for medical advice

**Procedure for reporting Adverse Drug Reactions (ADRs)**

All ADRs/ significant events/ near misses occurring in relation to the administration of this medicine under the PGD must be reported in the clinical record and the CCG incident reporting system.
The GP must be informed and, in a case requiring hospital admission or resulting in serious harm, the incident reported on a yellow card to the Committee on the Safety of Medicines (CSM) - [http://www.bnf.org/bnf/bnf/current/yellow.htm](http://www.bnf.org/bnf/bnf/current/yellow.htm).
**Appendix 1**

**Key references**

1. NICE Clinical Knowledge Summary Impetigo: [https://cks.nice.org.uk/impetigo](https://cks.nice.org.uk/impetigo)
4. e MC SmPC Fusidic Acrid Cream: [https://www.medicines.org.uk/emc/product/4061/smpc](https://www.medicines.org.uk/emc/product/4061/smpc)
5. e MC Fusidic Acrid Cream PIL: [https://www.medicines.org.uk/emc/product/4061/pil](https://www.medicines.org.uk/emc/product/4061/pil)

**Appendix 2**

Pharmacist Payment

<table>
<thead>
<tr>
<th></th>
<th>Drug Tariff (Jan 2018)</th>
<th>PharmOutcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacist Clinical Consultation</td>
<td>15g £1.48</td>
<td>£15.00</td>
</tr>
</tbody>
</table>

**Appendix 3**

**PharmOutcomes**

The system will factor invoices:

- Where ‘Product Supplied’ = The value of ‘Product Supplied (DM&D)’ x ‘Quantity Supplied in pence plus VAT at Standard rate (Product Reimbursement/Treatment Supplied)
- £15.00 per recorded service provision (VAT Exempt) (Consultation)
- ‘FP10 charges collected’ = Yes x - the NHS Prescription Levy for the period appropriate to the provision (Zero VAT) (Levy Charge)

The system will allow data to be claimed for at the time of issue. Payment by Commissioner will be quarterly.